



Property of Palmetto Infusion Services / CONFIDENTIAL Property of Palmetto Infusion Services / CONFIDENTIAL Property of Palmetto Infusion Services / CONFIDENTIAL Property of Palmetto Infusion Services / CONFIDENTIAL Property of Palmetto Infusion Services

MRN: \_\_\_\_\_

**Phone: 1-800-809-1265 Fax: 1-866-872-8920**

DOB: \_\_\_\_\_

## STANDARD Skyrizi® (Risankizumab-rzaa) PLAN OF TREATMENT

**NOTE:** Patient *may be ineligible* to receive Skyrizi® (risankizumab) if receiving antibiotics for active infectious process, antifungal infection, active fever and/or suspected infection.

**1. Patient Name:** \_\_\_\_\_ Height (inches): \_\_\_\_\_ Weight (lbs): \_\_\_\_\_

**2. Allergies:** \_\_\_\_\_

**3. Diagnosis:**  L40.0 Psoriasis Vulgaris  
 Other ICD-10 \_\_\_\_\_ Diagnosis description: \_\_\_\_\_

*CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion*

### **4. Dose/Frequency:**

Skyrizi 150mg administered subcutaneously at week 0, week 4, and every 12 weeks thereafter.

**Special orders:** \_\_\_\_\_

***If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES***

**5. Physician's Signature:** \_\_\_\_\_ / \_\_\_\_\_ Date: \_\_\_\_\_  
No Stamp Signatures (Dispense as written) Substitution permitted)

Printed Physician's Name with Credentials: \_\_\_\_\_ NPI: \_\_\_\_\_

### **6. Fax updated supporting clinical MD notes with each order renewal or change in orders**

*Infusion order forms and Adverse Drug Reaction Guidelines are available at [www.palmettoinfusion.com](http://www.palmettoinfusion.com)*

Revised 6/10/19



MRN: \_\_\_\_\_

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: \_\_\_\_\_

### Guidelines for Prescribing Skyrizi® (risankizumab-rzaa) for Dermatology (Required documentation with all initial referrals)

Patient Name: \_\_\_\_\_

Referral Date: \_\_\_\_\_

\_\_\_ Include signed and completed **Plan of Treatment**. (MD must complete sections 1-5)  
(Infusion order forms & Standard Adverse Reactions orders are available at [www.palmettoinfusion.com](http://www.palmettoinfusion.com) under Agency/MD tab)

\_\_\_ Include patient demographic information and insurance information. (Copy of insurance cards if available)

\_\_\_ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**

- Skyrizi® is indicated for **the treatment of moderate-to-severe plaque psoriasis** in adults who are candidates for systemic or phototherapy.

\_\_\_ Other as requested: \_\_\_\_\_  
\_\_\_\_\_

**Pre-Screening:** (TB results must be available prior to start of therapy and within last 12 months.)

\_\_\_ **Required TB screening results: PPD or QuantiFERON Gold Test.**  
(\* If screening results are positive or indeterminate, then a negative CXR result is required.)

\_\_\_ Vaccinations: Live vaccines should be avoided during treatment with Skyrizi.

*\*Product information suggests that patients who have stopped treatment for an extended period are at higher risk for hypersensitivity reactions. MD should evaluate premedication and consider antibody testing prior to restart of therapy.*

\*\*Warning/Precautions: Infections: SKYRIZI may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If such an infection develops, do not administer SKYRIZI until the infection resolves. • Tuberculosis (TB): Evaluate for TB prior to initiating treatment with SKYRIZI. See full prescribing information

Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.

**Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.**